Substituted 2H-isoquinolin-1-ones as potent Rho-kinase inhibitors: part 3, aryl substituted pyrrolidines.

The discovery and SAR of a series of beta-aryl substituted pyrrolidine 2H-isoquinolin-1-one inhibitors of Rho-kinase (ROCK) derived from 2 is herein described. SAR studies have shown that aryl groups in the beta-position are optimal for potency. Our efforts focused on improving the ROCK potency of this isoquinolone class of inhibitors which led to the identification of pyrrolidine 32 which demonstrated a 10-fold improvement in aortic ring (AR) potency over 2.

[1]  V. Niggli.  Rho‐kinase in human neutrophils: a role in signalling for myosin light chain phosphorylation and cell migration , 1999, FEBS letters.

[2]  A. Padwa,et al.  Use of N-[(trimethylsilyl)methyl]amino ethers as capped azomethine ylide equivalents , 1987 .

[3]  R. Stavenger.  Chapter 6 - Rho-Kinase Inhibitors for Cardiovascular Disease , 2008 .

[4]  Anne J. Ridley,et al.  ROCKs: multifunctional kinases in cell behaviour , 2003, Nature Reviews Molecular Cell Biology.

[5]  K. Kaibuchi,et al.  Formation of Actin Stress Fibers and Focal Adhesions Enhanced by Rho-Kinase , 1997, Science.

[6]  F. Ujjainwalla,et al.  Design and syntheses of melanocortin subtype-4 receptor agonists. Part 2: discovery of the dihydropyridazinone motif. , 2005, Bioorganic & medicinal chemistry letters.

[7]  M. Oka,et al.  Therapeutic potential of RhoA/Rho kinase inhibitors in pulmonary hypertension , 2008, British journal of pharmacology.

[8]  W. Hagmann,et al.  Addressing the metabolic activation potential of new leads in drug discovery: a case study using ion trap mass spectrometry and tritium labeling techniques. , 2003, Journal of mass spectrometry : JMS.

[9]  G. Zaloga,et al.  Diverse signaling pathways regulate fibroblast differentiation and transformation through Rho kinase activation , 2007, Journal of cellular physiology.

[10]  P. Ganz,et al.  Rho Kinase Inhibition Improves Endothelial Function in Human Subjects With Coronary Artery Disease , 2006, Circulation research.

[11]  Kazuo Katoh,et al.  Rho‐kinase dependent organization of stress fibers and focal adhesions in cultured fibroblasts , 2007, Genes to cells : devoted to molecular & cellular mechanisms.

[12]  D. Behm,et al.  Novel Rho Kinase Inhibitors with Anti-inflammatory and Vasodilatory Activities , 2007, Journal of Pharmacology and Experimental Therapeutics.

[13]  S. Offermanns,et al.  Rho/Rho-kinase mediated signaling in physiology and pathophysiology , 2002, Journal of Molecular Medicine.

[14]  K. Kaibuchi,et al.  Rho-kinase phosphorylates eNOS at threonine 495 in endothelial cells. , 2007, Biochemical and biophysical research communications.

[15]  R. L. Simões,et al.  Involvement of the Rho-Kinase/Myosin Light Chain Kinase Pathway on Human Monocyte Chemotaxis Induced by ATL-1, an Aspirin-Triggered Lipoxin A4 Synthetic Analog1 , 2005, The Journal of Immunology.

[16]  P. Loetscher,et al.  Rho kinase is required for CCR7‐mediated polarization and chemotaxis of T lymphocytes , 2003, FEBS Letters.

[17]  K. Akimoto,et al.  Fasudil, a Rho-kinase inhibitor, reverses L-NAME exacerbated severe nephrosclerosis in spontaneously hypertensive rats , 2008, Journal of hypertension.

[18]  P. Lograsso,et al.  Detection of myosin light chain phosphorylation--a cell-based assay for screening Rho-kinase inhibitors. , 2008, Biochemical and biophysical research communications.

[19]  K. Kaibuchi,et al.  Regulation and functions of Rho-associated kinase. , 2000, Experimental cell research.